Christopher Sweeney at ASCO GU 2026: Managing mHSPC and How Treatment Now Extends Overall Survival

Christopher Sweeney is a leading medical oncologist specializing in prostate cancer and a key figure in shaping modern treatment standards for advanced disease. In his ASCO GU 2026 talk he translates decades of clinical‑trial data into a practical, numbers‑driven framework for mHSPC therapy.

His talk on metastatic hormone‑sensitive prostate cancer (mHSPC) is built around a clear, data‑driven message: modern treatment significantly extends overall survival compared with older approaches. He frames current advances against the 1990s, when ADT alone led to about 25% 8‑year overall survival in advanced disease. Today, with ADT combined with ARPIs and/or docetaxel, that 8‑year overall survival has roughly doubled to around 50%, showing that these regimens are not just delaying progression but truly prolonging life.

A key landmark Sweeney highlights is the CHAARTED trial, which showed that adding docetaxel to ADT improved overall survival in mHSPC, especially in high‑volume disease. In high‑volume, synchronous metastases, adding docetaxel cut the risk of death by about one‑third, with hazard ratios for death around 0.63–0.72. In high‑volume but metachronous disease, the benefit is smaller but still present, with hazard ratios usually between 0.72 and 0.78. More recent real‑world data confirm that any combination including ADT plus an ARPI or docetaxel is associated with better survival than ADT alone, and the differences between ARPI‑ and docetaxel‑based doublets are smaller than the gap between doublets and monotherapy.

Sweeney also stresses that deep PSA responses are tightly linked to survival. In trials like CHAARTED and ENZAMET, patients who reach a PSA less than 0.2 ng/mL on ADT‑based therapy have a 50% overall survival at 8 years, making this a strong prognostic marker. Intensified regimens, such as triplet therapy (ADT + ARPI + docetaxel) or adding targeted agents, are more likely to push patients into this deep response range, and that is one reason they translate into better survival. For example, adding ¹⁷⁷Lu‑PSMA‑617 to ADT‑based therapy has produced a radiographic progression‑free survival hazard ratio of about 0.72, with an overall survival hazard ratio still below 1, indicating a real, albeit modest, survival signal in selected subgroups.

Beyond the numbers, Sweeney organizes his talk around how to use these data in practice. He argues that ADT plus an ARPI should be the backbone of treatment for all eligible mHSPC patients, and that adding docetaxel should be reserved for those who can tolerate chemotherapy and are most likely to benefit, particularly those with high‑volume disease. In synchronous low‑volume disease, many experts now add prostate‑directed SBRT, while in synchronous high‑volume disease there is strong consensus to add docetaxel because of its proven survival gain.

A major theme is biomarker‑driven optimization. Sweeney notes that agents such as PARP inhibitors, AKT inhibitors, and ¹⁷⁷Lu‑PSMA‑617 can improve progression‑free survival in some mHSPC populations, but their overall survival benefits are still modest and come with extra toxicity. He argues that these drugs should mainly be used in biomarker‑selected patients or within clinical trials, not as routine intensification for everyone. At the same time, ongoing trials exploring treatment breaks after a defined period of ADT‑based therapy and doublet versus triplet regimens aim to clarify who can be de‑escalated safely and who still needs the most intensive combinations.

Sweeney’s overall message is that today’s mHSPC strategies already extend life, and the task now is to refine them, so that each patient gets a regimen that maximizes survival gain while minimizing unnecessary toxicity.

Source.